FoxO1 regulates asymmetric dimethylarginine via downregulation of dimethylaminohydrolase 1 in human endothelial cells and subjects with atherosclerosis

Atherosclerosis

Volumn 242, Issue 1, 2015, Pages 230-235

  Menghini, Rossella ^a   Casagrande, Viviana ^a   Cardellini, Marina ^a   Ballanti, Marta ^a   Davato, Francesca ^a   Cardolini, Iris ^a   Stoehr, Robert ^a   Fabrizi, Marta ^a   Morelli, Monica ^a   Anemona, Lucia ^a   Bernges, Isabel ^b   Schwedhelm, Edzard ^b   Ippoliti, Arnaldo ^a   Mauriello, Alessandro ^a   Böger, Rainer H ^b   Federici, Massimo ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

ADMA; Atherosclerosis; Biomarker; Endothelium; FoxO1

Indexed keywords

DIMETHYLAMINOHYDROLASE 1; DIMETHYLARGININASE; GREEN FLUORESCENT PROTEIN; N(G),N(G) DIMETHYLARGININE; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; AMIDASE; ARGININE; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; N,N-DIMETHYLARGININE;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METABOLOME; METABOLOMICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CAROTID ARTERY DISEASE; CELL CULTURE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; METABOLISM; MUTATION; PROCEDURES; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

AMIDOHYDROLASES; ARGININE; CAROTID ARTERY DISEASES; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; METABOLOMICS; MUTATION; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84938060435     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.07.026     Document Type: Article

References (39)

1. Furuyama T., et al. Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J. Biol. Chem. 2004, 279:34741-34749.
2. Paik J.H., et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007, 128:309-323.
3. Potente M., et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J. Clin. Invest. 2005, 115:2382-2392.
4. Tanaka J., et al. Foxo1 links hyperglycemia to LDL oxidation and endothelial nitric oxide synthase dysfunction in vascular endothelial cells. Diabetes 2009, 58:2344-2354.
5. Oellerich M.F., Potente M. FOXOs and sirtuins in vascular growth, maintenance, and aging. Circ. Res. 2012, 110:1238-1251.
6. Tsuchiya K., et al. FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab. 2012, 15:372-381.
7. Daitoku H., Sakamaki J., Fukamizu A. Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim. Biophys. Acta 2011, 1813:1954-1960.
8. Huang H., Tindall D.J. Dynamic FoxO transcription factors. J. Cell Sci. 2007, 120:2479-2487.
9. Kitamura Y.I., et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab. 2005, 2:153-163.
10. Brunet A., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
11. Qiang L., Banks A.S., Accili D. Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization. J. Biol. Chem. 2010, 285:27396-27401.
12. Qiang L., et al. Increased atherosclerosis and endothelial dysfunction in mice bearing constitutively deacetylated alleles of Foxo1 gene. J. Biol. Chem. 2012, 287:13944-13951.
13. Roberts L.D., Gerszten R.E. Toward new biomarkers of cardiometabolic diseases. Cell Metab. 2013, 18:43-50.
14. Nakae J., et al. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J. Clin. Invest. 2001, 108:1359-1367.
15. Kitamura T., et al. A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. J. Clin. Invest. 2007, 117:2477-2485.
16. Matsumoto M., et al. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J. Clin. Invest. 2006, 116:2464-2472.
17. Reitman Z.J. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3270-3275.
18. Evans A.M., et al. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal. Chem. 2009, 81:6656-6667.
19. DeHaven C.D., et al. Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J. Chem. Inf. 2010, 2:9.
20. Menghini R., et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 2009, 120:1524-1532.
21. Caraux G., Pinloche S. PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics 2005, 21:1280-1281.
22. Vallance P., et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
23. Hsu C.P., et al. Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure. Atherosclerosis 2012, 225:504-510.
24. Lu T.M., et al. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int. J. Cardiol. 2011, 153:135-140.
25. Hu X., et al. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1540-1546.
26. Ding H., et al. A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease. Circ. Res. 2010, 106:1145-1152.
27. Von Leitner E.C., et al. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation 2011, 124:2735-2745.
28. Jacobi J., et al. Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. Am. J. Pathol. 2010, 176:2559-2570.
29. Gutiérrez E., et al. Endothelial dysfunction over the course of coronary artery disease. Eur. Heart J. 2013, 34:3175-3181.
30. Mauriello A., et al. Asymptomatic carotid plaque rupture with unexpected thrombosis over a non-canonical vulnerable lesion. Atherosclerosis 2011, 218:356-362.
31. Bouras G., et al. Asymmetric dimethylarginine (ADMA): a promising biomarker for cardiovascular disease?. Curr. Top. Med. Chem. 2013, 13:180-200.
32. Päivä H., et al. Levels of asymmetrical dimethylarginine are predictive of brachial artery flow-mediated dilation 6 years later. The Cardiovascular Risk in Young Finns Study. Atherosclerosis 2010, 212:512-520.
33. Sen N., et al. Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion. Atherosclerosis 2011, 219:304-310.
34. Tousoulis D., et al. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J. Am. Coll. Cardiol. 2013, 62:667-676.
35. Yamagata K., et al. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol. Cell. 2008, 32:221-231.
36. Tanaka H., et al. Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice. Eur. J. Pharmacol. 2010, 645:185-191.
37. Nagashima T., et al. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol. Pharmacol. 2010, 78:961-970.
38. Li X., et al. New insight into Metformin action: regulation of ChREBP and FoXO1 activities in endothelial cells. Mol. Endocrinol. 2015, 10.1210/ME.2015-1090.
39. Ghosh C.C., et al. Drug repurposing screen identifies Foxo1-dependent angiopoietin-2 regulation in sepsis. Crit. Care Med. 2015, 43:e230-240.